Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling
Language: 
English
Abstract: 

Bone loss is one of the major complications of advanced cancers such as breast cancer, prostate cancer, and multiple myeloma; agents that can suppress this bone loss have therapeutic potential. Extensive research within the last decade has revealed that RANKL, a member of the tumor necrosis factor superfamily, plays a major role in cancer-associated bone resorption and thus is a therapeutic target. We investigated the potential of vitamin K3 analogue plumbagin (derived from Chitrak, an Ayurvedic medicinal plant) to modulate RANKL signaling, osteoclastogenesis, and breast cancer-induced osteolysis. Plumbagin suppressed RANKL-induced NF-κB activation in mouse monocytes, an osteoclast precursor cell, through sequential inhibition of activation of IκBα kinase, IκBα phosphorylation, and IκBα degradation. Plumbagin also suppressed differentiation of these cells into osteoclasts induced either by RANKL or by human breast cancer or human multiple myeloma cells. When examined for its ability to prevent human breast cancer-induced bone loss in animals, plumbagin (2 mg/kg body weight) administered via the intraperitoneal route significantly decreased osteolytic lesions, resulting in preservation of bone volume in nude mice bearing human breast tumors. Overall, our results indicate that plumbagin, a vitamin K analogue, is a potent inhibitor of osteoclastogenesis induced by tumor cells and of breast cancer-induced osteolytic metastasis through suppression of RANKL signaling.

Author(s): 
Sung, Bokyung
Oyajobi, Babatunde
Aggarwal, Bharat B.
Item Type: 
Journal Article
Publication Title: 
Molecular Cancer Therapeutics
Journal Abbreviation: 
Mol. Cancer Ther.
Publication Date: 
Feb 2012
Publication Year: 
2012
Pages: 
350-359
Volume: 
11
Issue: 
2
ISSN: 
1538-8514
DOI: 
10.1158/1535-7163.MCT-11-0731
Library Catalog: 
NCBI Published Medical (?)
Extra: 
PMID: 22090419 PMCID: PMC3277663

Turabian/Chicago Citation

Bokyung Sung, Babatunde Oyajobi and Bharat B. Aggarwal. Feb 2012. "Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling." Molecular Cancer Therapeutics 11: 2: 350-359. 10.1158/1535-7163.MCT-11-0731.

Wikipedia Citation

<ref> {{Cite journal | doi = 10.1158/1535-7163.MCT-11-0731 | issn = 1538-8514 | volume = 11 | pages = 350-359 | last = Sung | first = Bokyung | coauthors = Oyajobi, Babatunde, Aggarwal, Bharat B. | title = Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling | journal = Molecular Cancer Therapeutics | date = Feb 2012 | pmid = | pmc = }} </ref>